TIGEN
LIVE

Serial Number

79304640

Owner

Tigen Pharma SA

Attorney

Stacey Halpern

Filing Date

Nov 13, 2020

Add to watchlist:

No watchlists yet
View on USPTO

TIGEN Trademark

Serial Number: 79304640 • Registration: 6674502

TIGEN is a trademark filed by Tigen Pharma SA on November 13, 2020. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

Tigen Pharma SA (3 trademarks)

voie du Chariot 3

Entity Type: 33

Trademark Details

Filing Date

November 13, 2020

Registration Date

March 22, 2022

Published for Opposition

January 4, 2022

Goods & Services

Pharmaceutical products and medical preparations, namely, gene-modified and non-gene-modified cellular therapies for the treatment of localized and systemic malignant hematological and oncological diseases, genetic diseases, autoimmune diseases and infectious diseases

Chemical, biochemical, biological and biotechnological preparations, namely, polypeptides and proteins, for use in industry and science; chemical, biochemical, biological and biotechnological preparations, namely, polypeptides and proteins, for use in the development being the manufacture, and manufacture of reagents for industrial or scientific use; chemical, biochemical, biological and biotechnological preparations, namely, polypeptides or proteins, for use of laboratories, diagnostics and analyses for industrial or scientific use; chemical, biochemical, biological and biotechnological substances, namely, polypeptides and proteins, for use in the manufacture of pharmaceuticals

Medical services; pharmacy advice services, namely, pharmaceutical consultation; medical clinic services provided by medical laboratories for diagnostic purposes; preparation and dispensing of medication; preparation of prescriptions by pharmacists

Medical instruments, equipment and apparatus, namely, instruments, equipment and apparatus for cell and cell material collection, thawing, washing, selection, expansion, modification, harvesting, final formulation, freezing, storage and infusion into a patient in the fields of genetic diseases, autoimmune diseases, infectious diseases, localized and systemic malignant hematological and oncological diseases and other cell and cell-material based diseases and conditions

Scientific research, technological development of new products for third parties; medical research; scientific and industrial research in biotechnology, biology, diseases, genetic diseases, autoimmune diseases, infectious and tumor diseases and the treatment of diseases, genetic diseases, autoimmune diseases, infectious and tumor diseases; research in the field of biomedical and phytopharmaceutical technology; scientific laboratory services; pharmaceutical research and development services; scientific services, namely, development of medicines, active substances and vaccines; scientific services, namely, development of food supplement; design and development of computer hardware and software for use in medical and scientific research and in the development of new products, in research and development of new products in the field of biotechnology, biology, diseases, genetic diseases, autoimmune diseases, infectious diseases and tumor diseases and the treatment of diseases, genetic diseases, autoimmune diseases, infectious diseases and tumor diseases; upgrading, maintenance and rental of computer software; updating, maintenance and rental of computer software for use in medical and scientific research and in the development of new products, in research and development of new products in the field of biotechnology, biology, diseases, genetic diseases, autoimmune diseases, infectious diseases and tumor diseases and the treatment of diseases, genetic diseases, autoimmune diseases, infectious diseases and tumor diseases; software as a service (SaaS) services featuring software for controlling end-to-end process development, manufacturing, quality, and supply chain steps and featuring artificial intelligence search engine software to be used in medical and scientific research and in the development of new products in research and development of new products in the field of biotechnology, biology, diseases, genetic diseases, autoimmune diseases, infectious diseases and tumor diseases and the treatment of diseases, genetic diseases, autoimmune diseases, infectious diseases and tumor diseases; chemical and biological laboratory services

Filing History

LIMITATION OF GOODS RECEIVED FROM IB
Jun 13, 2025 LIMG
LIMITATION OF GOODS RECEIVED FROM IB
Jun 6, 2025 LIMG
NEW REPRESENTATIVE AT IB RECEIVED
Dec 31, 2023 NREP
FINAL DECISION TRANSACTION PROCESSED BY IB
Sep 5, 2022 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Aug 15, 2022 FICS
FINAL DISPOSITION PROCESSED
Aug 15, 2022 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Jun 22, 2022 FICR
REGISTERED-PRINCIPAL REGISTER
Mar 22, 2022 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jan 4, 2022 NPUB
PUBLISHED FOR OPPOSITION
Jan 4, 2022 PUBO
NOTIFICATION PROCESSED BY IB
Jan 1, 2022 GPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Dec 15, 2021 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Dec 15, 2021 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Dec 15, 2021 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Nov 29, 2021 CNSA
EXAMINER'S AMENDMENT ENTERED
Nov 29, 2021 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Nov 29, 2021 GNEN
EXAMINERS AMENDMENT E-MAILED
Nov 29, 2021 GNEA
EXAMINERS AMENDMENT -WRITTEN
Nov 29, 2021 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Nov 8, 2021 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Nov 8, 2021 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Nov 8, 2021 TROA
NEW REPRESENTATIVE AT IB RECEIVED
Aug 27, 2021 NREP
NEW REPRESENTATIVE AT IB RECEIVED
Aug 20, 2021 NREP
REFUSAL PROCESSED BY IB
May 31, 2021 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
May 7, 2021 RFCS
REFUSAL PROCESSED BY MPU
May 7, 2021 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
May 4, 2021 RFCR
NON-FINAL ACTION WRITTEN
May 3, 2021 CNRT
ASSIGNED TO EXAMINER
Apr 24, 2021 DOCK
APPLICATION FILING RECEIPT MAILED
Feb 23, 2021 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Feb 19, 2021 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Feb 18, 2021 REPR